CHOLECYSTOKININ CHOLESCINTIGRAPHY: Clinical Indications and Proper Methodology
Section snippets
PHYSIOLOGY OF CHOLESCYSTOKININ
Cholecystokinin is a 33–amino acid polypeptide endogenously secreted by the duodenal mucosa in response to a fatty meal. The C-terminal octapeptide is the physiologically active portion of the hormone. CCK has numerous gastrointestinal physiologic effects as shown in the following list:
Contracts and empties gallbladder
Relaxes sphincter of Oddi
Increases intestinal motility
Contracts pyloric sphincter
Inhibits gastric emptying
Relaxes gastroesophageal sphincter tone
Stimulates hepatic bile
SINCALIDE
In the United States, sincalide is the only commercially available form of CCK approved by the Food and Drug Administration. Sincalide is the physiologically active C-terminal octapeptide of CCK. Its use in radiology dates back to the days of oral cholecystography when it was given to evaluate gallbladder contraction. In the 1970s many investigators sought to determine if poor gallbladder contraction in response to fatty meal or CCK could be used to diagnose chronic acalculous cholecystitis.
Prolonged Fasting Before Cholescintigraphy
If a patient has not eaten for an extended period of time, the gallbladder becomes filled with thick viscous bile. During fasting there is no stimulus to gallbladder contraction; however, the gallbladder's function of concentrating bile continues. This jellylike material may prevent radiotracer (Tc 9m disofenin or mebrofenin) entry during cholescintigraphy and result in a false-positive study (gallbladder nonvisualization in a patient who does not have acute cholecystitis). It has long been
METHODOLOGY FOR CHOLECYSTOKININ INFUSION
It has long been known that a bolus infusion of sincalide can produce spasm of the neck of the gallbladder, resulting in poor contraction.50 The Food and Drug Administration–approved package insert recommends a 30- to 60-second infusion of 0.02 to 0.04 μg/kg sincalide. Many investigators sought to avoid this problem by giving a 1- to 3-minute infusion. For unclear reasons, they defined an abnormal GBEF as less than 35%. This methodology was never validated, however, and normal values were never
PROTOCOL FOR CHOLESCYSTOKIN
Routine hepatobiliary iminodiacetic acid (HIDA) study with Tc 99m mebrofenin × 60 minutes.
- 1
Nothing by mouth for 3 to 4 hours before HIDA study.
- 2
Pre-HIDA CCK infusion if patient has been fasting greater than 24 hours.
- 3
Infuse CCK similar to that described next.
- 4
Wait at least 30 minutes before radiopharmaceutical injection to allow time for gallbladder to relax.
- 5
Large-field-of-view γ camera.
- 6
Computer setup: 60 1-minute frames.
- 7
Patient setup: Patient supine with camera anteriorly.
- 8
Inject Tc
- 1
References (60)
- et al.
Cholecystokinin constricts the canine cystic duct
Gastroenterology
(1983) - et al.
Efficacy of quantitative hepatobiliary scintigraphy and fatty meal sonography for evaluating patients with suspected partial common duct obstruction
Gastroenterology
(1988) Augmented cholescintigraphy: Its role in detecting acute and chronic disorders of the hepatobiliary tree
Semin Nucl Med
(1991)CCK cholescysobraphy
Semin Roentgenol
(1976)- et al.
Effect of cholecystokinin on colonic motility and symptoms in patients with the irritable bowel syndrome
Lancet
(1973) - et al.
Radionuclide ejection fraction: A technique for quantitative analysis of motor function of the human gallbladder
Gastroenterology
(1981) - et al.
Measurement of gallbladder emptying sequentially using a single dose of 99mTc labeled hepatobiliary agent
Gastroenterology
(1982) - et al.
Cholecystokinin and morphine pharmacological intervention during 99m Tc–HIDA cholescintigraphy: A rational approach
Semin Nucl Med
(1996) - et al.
Quantitative cholescintigraphy: Assessment of gallbladder filling and emptying and duodenogastric reflux
Gastroenterology
(1980) - et al.
Acalculous biliary pain: Cholecystectomy alleviates symptoms in patients with abnormal cholescintigraphy
Gastroenterology
(1991)
Gallbladder dynamics induced by a fatty meal in normal subjects and patients with gallstones: Concise communication
J Nucl Med
Morphine augmentation increases gallbladder visualization in patients pretreated with cholecystokinin
J Nucl Med
Hepatoduodenal bile transit in cholecystectomized subjects
Dig Dis Sci
Cholecystokinin, cholecystography, sonography, and scintigraphy: Detection of chronic acalculous cholecystitis
AJR Am J Roentgenol
The dilated common duct sign: A potential indicator of a sphincter of Oddi dyskinesia
Clin Nucl Med
Sincalide-augmented quantitative hepatobiliary scintigraphy (QHBS): Definition of normal parameters and preliminary relationship between QHBS and sphincter of Oddi (SO) manometry in patients suspected of having SO dysfunction
J Nucl Med
Cholecystokinin cholecystography
JAMA
A test for patency of the cystic duct in acute cholecystitis
Ann Intern Med
Cholecystokinin cholescintigraphy: Detection of abnormal gallbladder motor function in patients with chronic acalculous gallbladder disease
J Nucl Med
Cholecystokinin cholecystography in the differential diagnosis of acalculous gallbladder disease
Am J Dig Dis
Use of CCK cholescintigraphy to differentiate choledochal cyst from the gallbladder
Clin Nucl Med
The use of hepatobiliary scintigraphy in patients with acalculous biliary colic
Arch Intern Med
Gallbladder contraction induced by cholecystokinin: Bolus injection or infusion?
BMJ
Delayed biliary-to-bowel transit in cholescintigraphy after cholecystokinin treatment
Radiology
Cholescintigraphy in the diagnosis of acute cholecystitis: Morphine augmentation is superior to delayed imaging
J Nucl Med
Biliary obstruction after cholecystectomy: Diagnosis with quantitative cholescintigraphy
Radiology
Optimization of octapeptide of cholecystokinin dose for gallbladder emptying.
The gallbladder emptying response to sequential exogenous and endogenous cholecystokinin
Nucl Med Commun
Quantitative biliary dynamics: Introduction of a new noninvasive scintigraphic technique
J Nucl Med
Biliary dyskinesia: Role of the sphincter of Oddi gallbladder and cholecystokinin
J Nucl Med
Cited by (0)
Address reprint requests to Harvey A. Ziessman, MD, Division of Nuclear Medicine, Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007. e-mail:[email protected]